Integrated BioTherapeutics, Rockville, USA.
Department of Chemistry, Washington University in St. Louis, St. Louis, USA.
MAbs. 2022 Jan-Dec;14(1):2083467. doi: 10.1080/19420862.2022.2083467.
carries an exceptional repertoire of virulence factors that aid in immune evasion. Previous single-target approaches for -specific vaccines and monoclonal antibodies (mAbs) have failed in clinical trials due to the multitude of virulence factors released during infection. Emergence of antibiotic-resistant strains demands a multi-target approach involving neutralization of different, non-overlapping pathogenic factors. Of the several pore-forming toxins that contribute to pathogenesis, efforts have largely focused on mAbs that neutralize α-hemolysin (Hla) and target the receptor-binding site. Here, we isolated two anti-Hla and three anti-Panton-Valentine Leukocidin (LukSF-PV) mAbs, and used a combination of hydrogen deuterium exchange mass spectrometry (HDX-MS) and alanine scanning mutagenesis to delineate and validate the toxins' epitope landscape. Our studies identified two novel, neutralizing epitopes targeted by 2B6 and CAN6 on Hla that provided protection from hemolytic activity in vitro and showed synergy in rodent pneumonia model against lethal challenge. Of the anti-LukF mAbs, SA02 and SA131 showed specific neutralization activity to LukSF-PV while SA185 showed cross-neutralization activity to LukSF-PV, γ-hemolysin HlgAB, and leukotoxin ED. We further compared these antigen-specific mAbs to two broadly neutralizing mAbs, H5 (targets Hla, LukSF-PV, HlgAB, HlgCB, and LukED) and SA185 (targeting LukSF-PV, HlgAB, and LukED), and identified molecular level markers for broad-spectrum reactivity among the pore-forming toxins by HDX-MS. To further underscore the need to target the cross-reactive epitopes on leukocidins for the development of broad-spectrum therapies, we annotated Hla sequences isolated from patients in multiple countries for genomic variations within the perspective of our defined epitopes.
它携带了异常丰富的毒力因子,有助于免疫逃逸。以前针对 - 的单一靶点疫苗和单克隆抗体 (mAb) 的方法在临床试验中都失败了,这是因为在感染过程中释放了多种毒力因子。抗生素耐药菌株的出现要求采用多靶点方法,包括中和不同的、不重叠的致病因子。在导致发病的几种孔形成毒素中,研究主要集中在中和 α-溶血素 (Hla) 并靶向受体结合位点的 mAb 上。在这里,我们分离出两种抗 Hla 和三种抗 Panton-Valentine Leukocidin (LukSF-PV) mAb,并结合氢氘交换质谱 (HDX-MS) 和丙氨酸扫描突变来描绘和验证毒素的表位图谱。我们的研究确定了两个新型的、由 2B6 和 CAN6 针对 Hla 的中和表位,这些表位在体外提供了对溶血活性的保护,并在啮齿动物肺炎模型中针对致命挑战显示出协同作用。在抗 LukF mAb 中,SA02 和 SA131 显示对 LukSF-PV 的特异性中和活性,而 SA185 显示对 LukSF-PV、γ-溶血素 HlgAB 和白细胞毒素 ED 的交叉中和活性。我们进一步将这些抗原特异性 mAb 与两种广泛中和的 mAb(H5(靶向 Hla、LukSF-PV、HlgAB、HlgCB 和 LukED)和 SA185(靶向 LukSF-PV、HlgAB 和 LukED))进行比较,并通过 HDX-MS 确定了孔形成毒素广谱反应性的分子水平标记物。为了进一步强调针对白细胞毒素的交叉反应表位开发广谱疗法的必要性,我们根据我们定义的表位,对来自多个国家的患者中分离的 Hla 序列进行了基因组变异注释。